• The Phase 2a “ZONE” study will evaluate the effect of ZT-01 on preventing nighttime hypoglycemia (low blood glucose) in people with Type 1 diabetes.
• Results of the Phase 1b proof-of-concept study were highly significant, and in many patients, ZT-01 caused a rise in glucagon and a corresponding rise in glucose that suggests that ZT-01 may prevent hypoglycemia in the ZONE study.
• ZT-01 has the potential to become the first therapeutic available to prevent hypoglycemia in people with Type 1 diabetes.

Read more there: https://bit.ly/3tdenYY